Stock 4503 ASTELLAS PHARMA INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Astellas Pharma Inc.

Equities

4503

JP3942400007

Market Closed - Japan Exchange
Other stock markets
 02:00:00 2024-07-05 am EDT 		5-day change 1st Jan Change
1,616 JPY +0.78% Intraday chart for Astellas Pharma Inc. +1.09% -4.12%
Jun. 03 US FDA Acknowledges Astellas Pharma's Resubmission of Biologics License Application for Zolbetuximab MT
May. 31 U.S. Food and Drug Administration Acknowledges Astellas Pharma Inc.? Resubmission of Biologics License Application for Zolbetuximab and Sets New Action Date CI

Evolution of the average Target Price on Astellas Pharma Inc.

Price target over the last 5 years

History of analyst recommendation changes

e1d54.RPK5U7OzMpEiLSKRhWpUjpWMXKmUVvN3AwcALq2e3-Y.FKL8BorpQNhbYFXG9w0X5aziDvryZ6pHekNQGuHOrIkLwNFq_9VjqUhYaw~96c7d5cd37736ff08ef6bc1c3c2780fc

Analyst Recommendations on Astellas Pharma Inc.

Jefferies Adjusts Astellas Pharma’s Price Target to 2,100 Yen From 2,200 Yen, Keeps at Buy MT
Jefferies Adjusts Astellas Pharma’s Price Target to 2,200 Yen From 2,400 Yen, Keeps at Buy MT
Jefferies Upgrades Astellas Pharma to Buy From Hold, Keeps Price Target at 2,400 Yen MT
Jefferies Adjusts Astellas Pharma's Price Target to 2,400 Yen From 2,300 Yen, Keeps at Buy MT
Jefferies Adjusts Astella Pharma’s Price Target to 2,300 Yen From 2,200 Yen, Keeps at Buy MT
Jefferies Upgrades Astellas Pharma to Buy From Hold, Adjusts Price Target to 2,200 Yen From 2,100 Yen MT
Seattle Genetics and Astellas Announce Antibody-Drug Conjugate Enfortumab Vedotin Produced Tumor Response Rate CI
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
1,604 JPY
Average target price
1,855 JPY
Spread / Average Target
+15.67%
High Price Target
2,300 JPY
Spread / Highest target
+43.39%
Low Price Target
1,200 JPY
Spread / Lowest Target
-25.19%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Astellas Pharma Inc.

Jefferies & Co.

Ratings for Astellas Pharma Inc.

Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. 4503 Stock
  4. Consensus Astellas Pharma Inc.